Absence of a clinically relevant interaction between etanercept and digoxin

Journal of Clinical Pharmacology

Volumn 44, Issue 11, 2004, Pages 1244-1251

  Zhou, Honghui ^a   Parks, Virginia ^b   Patat, Alain ^b   Le Coz, Franck ^c   Simcoe, Donna ^a   Korth Bradley, Joan ^a  

^a PFIZER INC   (United States)

^b Clinical Research and Development   (France)

^c Biotrial SA   (France)

Author keywords

Digoxin; Etanercept; Interaction

Indexed keywords

DIGOXIN; ETANERCEPT;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD SAMPLING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIARRHEA; DIGOXIN BLOOD LEVEL; DIZZINESS; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TOXICITY; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; INFECTION; INJECTION SITE; MALE; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NORMAL HUMAN; OPEN STUDY; PHARYNGITIS; RADIOIMMUNOASSAY; RESPIRATORY TRACT DISEASE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHINITIS; SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; CARDIOTONIC AGENTS; CROSS-OVER STUDIES; DIGOXIN; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 6344261597     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268050     Document Type: Article

References (37)

1. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244-247.
2. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995;38:151-160.
3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916.
4. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259.
5. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-1593.
6. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
7. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
8. Lebsack ME, Hanna RK, Lange MA, et al. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers [abstract 233]. Pharmacotherapy. 1997;17(5):1118.
9. European Agency for Evaluation of Medicinal Products. Scientific discussion: Enbrel [online]. Retrieved from www.emea.eu.int.
10. Zhou H, Buckwalter M, Boni J, et al. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004;42(5):267-276.
11. Zhou H, Buckwalter M, Mayer P, et al. Pharmacokinetics (PK) of etanercept are unaltered by concurrent administration of methotrexate (MTX) in rheumatoid arthritis (RA). Arthritis Rheum. 2003;48(9, Suppl.):S139.
12. Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol. 2004;44(5):543-550.
13. Reuning RH, Geraets DR, Rocci JL, Vlasses PH. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, Wash: Applied Therapeutics, 1992;20-48.
14. Simon R. Confidence intervals for reporting results of clinical trials. Ann Int Med. 1986;105:429-435.
15. US Food and Drug Administration. Guidance for industry: in vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling. Rockville, Md: Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, Nov 1999.
16. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br J Clin Pharmacol. 2003;56(Suppl. 1):45-50.
17. Feuring M, Lee Y, Orlowski LH, et al. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol. 2003;43(8):912-917.
18. Zussman BD, Kelly J, Murdoch RD, Clark DJ, Mbchb, Schubert C, Collie H. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin. Clin Ther. 2001;23(6):921-931.
19. Levy G. What are narrow therapeutic index drugs? Clin Pharmacol Ther. 1998;63(5):501-505.
20. Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000;34:161-164.
21. Collie H, Wargenau M. Planning of drug interaction studies involving digoxin treatment: a statistical view. Int J Clin Pharmacol Ther Toxicol. 1992;30(11):534-536.
22. Thomas RW, Maddox RR. The interaction of spironolactone and digoxin: a review and evaluation. Ther Drug Monit. 1981;3(2):117-120.
23. Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol. 1985;5(5, Suppl. A):82A-90A.
24. Bigger JT Jr, Leahey EB Jr. Quinidine and digoxin: an important interaction. Drugs. 1982;24(3):229-239.
25. Gordon M, Goldenberg LM. Clinical digoxin toxicity in the aged in association with coadministered verapamil: a report of two cases and review of the literature. J Am Geriatr Soc. 1986;34(9):659-662.
26. Opie LH. Calcium channel antagonists: Part IV. Side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther. 1988;2(2):177-189.
27. Koren G. Clinical pharmacokinetic significance of the renal tubular secretion of digoxin. Clin Pharmacokinet. 1987;13(5):334-343.
28. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology. 1984;86:174-193.
29. Bizjak ED, Mauro VF. Digoxin-macrolide drug interaction. Ann Pharmacother. 1997;31(9):1077-1079.
30. Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther. 2001;70:311-316.
31. Woodland C, Koren G, Ito S. From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxin-mifepristone example. J Clin Pharmacol. 2003;43:743-750.
32. Verstuyft C, Strabach S, Morabet HE, et al. Dipyridamole enhance digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther. 2003;73:51-60.
33. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38(2):69-74.
34. Rengelshausen J, Goggelmann C, Burhenne J, et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003;56:32-38.
35. Etanercept package insert, 2001.
36. Dockens RC, Greene DS, Barbhaiya RH. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol. 1996;36:160-167.
37. DeBoer A, Stiekema JC, Danhof M, Moolenaar AJ, Breimer DD. Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers. Eur J Clin Pharmacol. 1991;41:245-250.